Talk:Schrödinger, Inc.

Connected contributor
Review of edit history dating back to beginning, and that of the article starting user showed connection to company. Geolocate returns Special:Contributions/38.96.144.55 as Schrodinger designated IP. The frequent and nearly exclusive relationship of edits from Gsmith8 and Wikiscount03 are indicative of connected editingCantaloupe2 (talk) 04:57, 2 September 2013 (UTC)

Some proposed changes
Information to be added or removed: Removed promotional language like "leading", "robust", and "world class", and any unsubstantiated claims. Added that their software may "help" accelerate R&D to soften the claim. Explanation of issue: Please proofread the proposed changes and implement what you believe to be appropriate. I tried to provide only factual/substantiated facts and remove any promotional language.

Schrödinger's computational platform is deployed by pharmaceutical, biotechnology, chemical, and electronics companies to help accelerate R&D in both drug discovery and materials design. Schrödinger has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.

Founded in 1990, Schrödinger has approximately 400 employees in its New York City headquarters and around the world.

Schrödinger is headquartered in New York, but also has offices around the world including several offices in the U.S., two offices in Germany, and offices in India, Japan, the UK, and China. Bill Gates has invested a total of $100 million in Schrödinger since 2010. David E. Shaw is also a major investor in the company.

In 2019, Schrödinger closed a funding round of $110 million led by the Bill and Melinda Gates Foundation Trust and WuXi AppTec's Corporate Venture Fund. Other investors included Baron, Deerfield Management, GV (formerly Google Ventures), Invus, Laurion, Pavilion, Qiming Venture Partners, and Oculus co-founder Michael Antonov through his investment fund, Tubus Management.

Schrödinger is a co-founder of Nimbus Therapeutics, Morphic Therapeutic , Bright Angel Therapeutics and Faxian Therapeutics.

Schrödinger's platform integrates physics-based predictive simulation and machine learning to power “computational assays,” which evaluate compounds in silico on properties such as binding affinity and solubility. Schrödinger's full product offerings include molecular modeling programs and LiveDesign, an application designed to facilitate real-time collaboration and communication among interdisciplinary research teams around the globe. The full computational platform is used by nearly all major biopharma companies to speed drug discovery. It is also used for materials design in several industries, including organic light emitting diodes and energy storage.

Schrödinger provides professional services including custom software development and training, computer-cluster design and implementation, and research-based drug discovery projects. These professional services are provided to commercial, academic, and government organizations to assist with small-molecule design, biologics design, materials science applications, and implementation of enterprise-level informatics.

Schrödinger has a therapeutics pipeline including a number of partnerships and wholly owned programs. Schrödinger's partners include larger pharmaceutical companies, including Takeda and Sanofi, as well as many biotech startups around the world. These partnerships have led to two FDA-approved oncology drugs, several more clinical-stage assets and more than two dozen additional programs moving through discovery and development.

Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform in combination with a virtual, globally distributed model for drug discovery. In 2016, Nimbus Therapeutics sold an Acetyl-CoA Carboxylase (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion. As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH. In 2018, Morphic Therapeutic, also co-founded by Schrödinger, struck a multi-target deal with AbbVie to collaborate on the development of therapies for fibrotic diseases and in 2019 with Janssen (facilitated by Johnson & Johnson Innovation, Boston) on undisclosed integrin targets. Both of Morphic's partnerships will advance therapies designed through Schrödinger's computational platform.

Schrödinger launched their own internal drug discovery programs. The wholly owned programs will initially be focused on oncology but will add new programs in 2019.

Schrödinger founder Prof. Richard A. Friesner was elected to the National Academy of Sciences in 2016, and to the American Academy of Arts and Sciences in 2008. In 2014, Schrödinger was awarded the BioIT World Best Practices Award in the category of IT Infrastructure. In September 2013, Nimbus Therapeutics, which was co-founded by Schrödinger, was named one of Fierce Biotech's "2013 Fierce 15" in recognition of the company's novel business strategies and technology.

In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research. This work was a follow up to a collaboration in 2012 in which Cycle Computing created a 50,000 core virtual supercomputer using Amazon infrastructure and Schrödinger's Glide program was used to analyze 2.1 million compounds in only 3 hours.

— Preceding unsigned comment added by Ecreason (talk • contribs) 14:34, 6 September 2019 (UTC)

Reply 06-SEP-2019
Regards, Spintendo  17:22, 6 September 2019 (UTC)
 * Portions of the proposed text were found to be insufficiently paraphrased from the source material.
 * All additions to an article need to be placed using an editor's own words and phrases.
 * Kindly rewrite the proposal, taking care to ensure that information taken from sources is placed in your own words, and feel free to submit that proposal in a new post at the bottom of the talk page at your earliest convenience. The proposed text was re-edited by the reviewer and added to the article. See the update below for more information.


 * The article has been cleaned up to ensure NPOV. As a result, most of the maintenance templates were omitted, with the COI maintenance template being omitted in this last edit. Six out of the nine total references used in the article (67%) are to press releases — which is not ideal — but the promotional language used in those sources has been limited here in the article's paraphrased prose, leaving the article with just the right amount of needed information without too many embellishments. I feel that this allows the COI template to be withdrawn. Note to the COI editor: If there are any items currently left which are incorrect, please advise. With regards to the Pipeline section, whereas the information on Nimbus' deal with Gilead was left because it was specific information regarding the ACC inhibitor sold to Gilead — the information on Morphic's "multi-target deal" was not added, as it was non-specific. Regards, Spintendo  20:23, 6 September 2019 (UTC)

Reply 26-SEP-2019
Thank you Spintendo The first sentence is incorrect as Schrödinger is not a life sciences company. I'd like to request the following edits, as well as combining the Products and Services section into the overview section so that it reads as follows. Please review:

Schrödinger was founded in 1990 and is headquartered in New York City. Schrödinger's computational platform evaluates compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. Schrödinger's products include molecular modeling programs and LiveDesign, an enterprise application designed to facilitate communication among interdisciplinary research teams.[1] Their computational platform is also deployed in many research-based drug discovery projects and collaborations. In addition to its computational platform, Schrödinger provides professional services, including custom software development and training, computer-cluster design and implementation.[2][3] — Preceding unsigned comment added by Ecreason (talk • contribs) 20:51, 26 September 2019 (UTC)

Proposed updated company description
Information to be added or removed: Please replace "Schrödinger is a life sciences and materials science company founded in 1990 that develops software for computational chemistry. The company is headquartered in New York City." with "Schrödinger, Inc. an American multinational biopharmaceutical and technology company headquartered in New York City." Explanation of issue: The current company description is no longer accurate, as the company has evolved its business in past years. References supporting change: https://www.fiercebiotech.com/cro/big-pharma-partner-schrodinger-wants-a-100-million-ipo, https://endpts.com/shooting-for-100m-ipo-schro%cc%88dinger-takes-the-wraps-off-its-five-internal-drugs-and-discloses-deal-details/ , https://xconomy.com/new-york/2020/01/14/schrodinger-sets-course-for-ipo-to-support-growing-internal-pipeline/ Ecreason (talk) 21:12, 27 April 2020 (UTC)
 * Please provide the necessary Wikilinks for these terms. Regards, Spintendo  17:05, 2 May 2020 (UTC)
 * Is this what is needed? Schrödinger, Inc. an American multinational biopharmaceutical and technology company headquartered in New York City. Ecreason (talk) 19:22, 20 May 2020 (UTC)